JP2017538769A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538769A5 JP2017538769A5 JP2017533416A JP2017533416A JP2017538769A5 JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5 JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017533416 A JP2017533416 A JP 2017533416A JP 2017538769 A5 JP2017538769 A5 JP 2017538769A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- solvate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000012453 solvate Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- QEUAUMWHNLVMDZ-HXUWFJFHSA-N 6-(5-fluoroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound FC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C QEUAUMWHNLVMDZ-HXUWFJFHSA-N 0.000 claims 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims 1
- OJVNYQOKTZLPPX-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O OJVNYQOKTZLPPX-OAQYLSRUSA-N 0.000 claims 1
- URFCQPHIMBZYON-OAQYLSRUSA-N 3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-6-(5-methylquinolin-7-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCCC1)=O)C=1C(NC(=CC=1)C1=CC(=C2C=CC=NC2=C1)C)=O URFCQPHIMBZYON-OAQYLSRUSA-N 0.000 claims 1
- NYMPHOZUBJYHBQ-HXUWFJFHSA-N 3-[(3R)-3-methyl-2-oxopyrrolidin-3-yl]-6-(5-methylquinolin-3-yl)-1H-pyridin-2-one Chemical compound C[C@]1(C(NCC1)=O)C=1C(NC(=CC=1)C=1C=NC2=CC=CC(=C2C=1)C)=O NYMPHOZUBJYHBQ-HXUWFJFHSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- ALGSMAYBBGCDSR-HXUWFJFHSA-N 6-(5-chloroquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound ClC1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C ALGSMAYBBGCDSR-HXUWFJFHSA-N 0.000 claims 1
- JXKXDDNPECXKSM-HSZRJFAPSA-N 6-(5-cyclopropylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C1(CC1)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C JXKXDDNPECXKSM-HSZRJFAPSA-N 0.000 claims 1
- KPRFPENKXRBQRF-JOCHJYFZSA-N 6-(5-ethylquinolin-7-yl)-3-[(3R)-3-methyl-2-oxopiperidin-3-yl]-1H-pyridin-2-one Chemical compound C(C)C1=C2C=CC=NC2=CC(=C1)C1=CC=C(C(N1)=O)[C@@]1(C(NCCC1)=O)C KPRFPENKXRBQRF-JOCHJYFZSA-N 0.000 claims 1
- ICRVRXNPWUOCMP-IVAFLUGOSA-N CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O Chemical compound CCc1cc(cc2ncccc12)C1=NC(=O)C(C=C1)[C@@]1(C)CCCNC1=O ICRVRXNPWUOCMP-IVAFLUGOSA-N 0.000 claims 1
- ZTBLZTHRYZXYNZ-WBPHRXDCSA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(C2CC2)c2cccnc2c1 ZTBLZTHRYZXYNZ-WBPHRXDCSA-N 0.000 claims 1
- SGMZEERLWJABMZ-YBMSBYLISA-N C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 Chemical compound C[C@@]1(CCCNC1=O)C1C=CC(=NC1=O)c1cc(Cl)c2cccnc2c1 SGMZEERLWJABMZ-YBMSBYLISA-N 0.000 claims 1
- SSQLJNRCSCKPFA-MYKUNDNFSA-N Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cc(cc2ncccc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O SSQLJNRCSCKPFA-MYKUNDNFSA-N 0.000 claims 1
- ZUCVEFCHDRKBHT-MYKUNDNFSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCCNC1=O ZUCVEFCHDRKBHT-MYKUNDNFSA-N 0.000 claims 1
- RXTUYFXTGPOYIV-ALLBUHFWSA-N Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O Chemical compound Cc1cccc2ncc(cc12)C1CCC(C(=O)N1)[C@@]1(C)CCNC1=O RXTUYFXTGPOYIV-ALLBUHFWSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000007614 solvation Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095337P | 2014-12-22 | 2014-12-22 | |
| US62/095,337 | 2014-12-22 | ||
| US201562259528P | 2015-11-24 | 2015-11-24 | |
| US62/259,528 | 2015-11-24 | ||
| PCT/IB2015/059548 WO2016103097A1 (en) | 2014-12-22 | 2015-12-11 | Antagonists of prostaglandin ep3 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538769A JP2017538769A (ja) | 2017-12-28 |
| JP2017538769A5 true JP2017538769A5 (en:Method) | 2019-01-24 |
Family
ID=55077554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533416A Withdrawn JP2017538769A (ja) | 2014-12-22 | 2015-12-11 | プロスタグランジンｅｐ３受容体の拮抗薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9738626B2 (en:Method) |
| EP (1) | EP3237401B1 (en:Method) |
| JP (1) | JP2017538769A (en:Method) |
| CA (1) | CA2915470A1 (en:Method) |
| TW (1) | TW201632513A (en:Method) |
| UY (1) | UY36455A (en:Method) |
| WO (1) | WO2016103097A1 (en:Method) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
| US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
| US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
| WO2019219517A1 (en) | 2018-05-17 | 2019-11-21 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| IL307374A (en) | 2021-04-07 | 2023-11-01 | Hadasit Med Res Service | EP3 antagonists for the treatment of diabetes |
| CN116106398A (zh) * | 2022-08-03 | 2023-05-12 | 南方医科大学珠江医院 | 用于诊断ckd的标志物 |
| KR20260011665A (ko) * | 2023-03-13 | 2026-01-23 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 화합물 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| TR200100149T2 (tr) | 1998-07-06 | 2001-10-22 | Bristol-Myers Squibb Company | Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| ES2283550T3 (es) | 2001-02-28 | 2007-11-01 | MERCK & CO., INC. | Derivados de piperidina acilados como antagonistas del receptor de. |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| IL163659A0 (en) | 2002-02-27 | 2005-12-18 | Pfizer Prod Inc | Acc inhibitors |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2005116014A1 (en) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| CN101052397B (zh) | 2004-08-26 | 2011-07-06 | 埃科特莱茵药品有限公司 | 2-硫烷基-苯并咪唑-1-基-乙酸衍生物 |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US20080200568A1 (en) | 2005-08-30 | 2008-08-21 | Stephanie Chissoe | Genes Associated With Type ll Diabetes Mellitus |
| PT2463283E (pt) | 2006-04-20 | 2014-08-27 | Pfizer Prod Inc | Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase |
| ATE552262T1 (de) | 2006-11-29 | 2012-04-15 | Pfizer Prod Inc | Spiroketone als inhibitoren von acetyl-coa- carboxylase |
| EP2155666A1 (en) | 2007-05-10 | 2010-02-24 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
| AP2524A (en) | 2007-05-11 | 2012-12-04 | Pfizer | Amino-heterocyclic compounds |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
| WO2010023594A1 (en) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| DK2406253T3 (da) | 2009-03-11 | 2013-08-12 | Pfizer | Benzofuranylderivater anvendt som glucokinase-inhibitorer |
| JP2012520868A (ja) | 2009-03-20 | 2012-09-10 | ファイザー・インク | ３−オキサ−７−アザビシクロ［３．３．１］ノナン |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| SG175995A1 (en) | 2009-06-05 | 2011-12-29 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| PH12013501556A1 (en) | 2011-02-23 | 2017-10-25 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| JP2014516074A (ja) | 2011-06-07 | 2014-07-07 | ファイザー・インク | ピラゾロ［３，４−ｄ］ピリミジン化合物ならびにそのＰＤＥ２阻害剤および／またはＣＹＰ３Ａ４阻害剤としての使用 |
| CA2926568C (en) * | 2013-10-09 | 2017-09-05 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
-
2015
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en not_active Ceased
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538769A5 (en:Method) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2017504635A5 (en:Method) | ||
| JP2013523802A5 (en:Method) | ||
| JP2016521710A5 (en:Method) | ||
| JP2015522650A5 (en:Method) | ||
| JP2013542261A5 (en:Method) | ||
| JP2012140432A5 (en:Method) | ||
| JP2017509586A5 (en:Method) | ||
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| JP2016530259A5 (en:Method) | ||
| JP2017517512A5 (en:Method) | ||
| JP2016501250A5 (en:Method) | ||
| JP2016507581A5 (en:Method) | ||
| JP2016518328A5 (en:Method) | ||
| WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
| JP2015512883A5 (en:Method) | ||
| JP2017526701A5 (en:Method) | ||
| JP2017506666A5 (en:Method) | ||
| JP2017537937A5 (en:Method) | ||
| JP2016528273A5 (en:Method) | ||
| JP2015500842A5 (en:Method) | ||
| JP2013502441A5 (en:Method) | ||
| JP2016028076A5 (en:Method) | ||
| HRP20192279T1 (hr) | Novi spojevi imidazopiridazina i njihova uporaba |